1. Lubiprostone increases intraluminal fluid in chronic constipation. Which molecular target does lubiprostone activate to produce this effect?
A) Guanylate cyclase-C (GC-C) receptors on the luminal epithelial surface
B) Type-2 chloride (ClC-2) channels on the apical surface of intestinal epithelial cells
C) The sodium/hydrogen exchanger isoform 3 (NHE3)
D) Mu-opioid receptors in the myenteric plexus
E) 5-hydroxytryptamine type 3 (5-HT3) receptors on primary afferent neurons
ANSWER: B
Rationale:
Option B is correct. Lubiprostone, a bicyclic fatty acid derived from prostaglandin E1, activates type-2 chloride (ClC-2) channels on the apical membrane of intestinal epithelial cells. Chloride moves into the lumen and water follows, increasing intraluminal fluid and accelerating transit.
Option A: Option A is incorrect. GC-C receptor agonism is the mechanism of linaclotide and plecanatide, not lubiprostone.
Option C: Option C is incorrect. NHE3 inhibition is the mechanism of tenapanor.
Option D: Option D is incorrect. Mu-opioid receptor activity in the myenteric plexus relates to opioids and to peripherally acting antagonists, not to lubiprostone.
Option E: Option E is incorrect. 5-HT3 receptor activity relates to alosetron, not to lubiprostone.
2. Among the peripherally acting mu-opioid receptor antagonists (PAMORAs) used for opioid-induced constipation, which agent is a CYP3A4 substrate such that strong CYP3A4 inhibitors are contraindicated?
A) Methylnaltrexone
B) Naldemedine
C) Alvimopan
D) Naloxegol
E) Lubiprostone
ANSWER: D
Rationale:
Option D is correct. Naloxegol is metabolized by CYP3A4. Strong CYP3A4 inhibitors (for example, ketoconazole and clarithromycin) markedly raise naloxegol concentrations and are contraindicated, while moderate inhibitors require dose reduction.
Option A: Option A is incorrect. Methylnaltrexone, a quaternary ammonium derivative of naltrexone, is not characterized by this CYP3A4 contraindication; its peripheral selectivity comes from its charged structure.
Option B: Option B is incorrect. Naldemedine is a once-daily PAMORA but is not the agent defined by the strong-CYP3A4-inhibitor contraindication taught for naloxegol.
Option C: Option C is incorrect. Alvimopan is used for postoperative ileus, not the agent associated with the naloxegol CYP3A4 contraindication.
Option E: Option E is incorrect. Lubiprostone is a chloride-channel secretagogue, not a PAMORA.
3. Which peripherally acting mu-opioid receptor antagonist (PAMORA) is a quaternary ammonium derivative of naltrexone whose permanent positive charge limits central nervous system penetration?
A) Methylnaltrexone
B) Naloxegol
C) Naldemedine
D) Eluxadoline
E) Loperamide
ANSWER: A
Rationale:
Option A is correct. Methylnaltrexone is a quaternary ammonium derivative of naltrexone. The quaternary nitrogen carries a permanent positive charge that substantially limits central nervous system penetration, confining antagonist activity to peripheral mu-opioid receptors in the gut. It is available subcutaneously and orally.
Option B: Option B is incorrect. Naloxegol achieves central exclusion through PEGylation and P-glycoprotein efflux, not a quaternary ammonium charge.
Option C: Option C is incorrect. Naldemedine reduces blood-brain barrier penetration through a bulky side chain, not a quaternary charge.
Option D: Option D is incorrect. Eluxadoline is a mixed opioid receptor modulator for IBS-D, not a quaternary ammonium PAMORA.
Option E: Option E is incorrect. Loperamide is an antidiarrheal mu-opioid agonist excluded from the brain by P-glycoprotein, not a PAMORA.
4. Bisacodyl is classified as a stimulant laxative. Which description correctly characterizes its mechanism?
A) It is a non-absorbed polymer that retains an obligate osmotic water load
B) It is a non-absorbable disaccharide fermented by colonic bacteria
C) It is converted by intestinal esterases to an active form that directly stimulates secretomotor neurons in the submucosal plexus and increases propulsive motility
D) It binds bile acids in the lumen as an anion-exchange resin
E) It activates guanylate cyclase-C (GC-C) receptors to raise cyclic guanosine monophosphate
ANSWER: C
Rationale:
Option C is correct. Bisacodyl is converted by intestinal esterases to its active form, which directly stimulates secretomotor neurons in the submucosal plexus and increases propulsive motility. Its oral onset is roughly 6 to 12 hours, making it suitable for short-term and rescue use.
Option A: Option A is incorrect. A non-absorbed polymer with an obligate osmotic water load describes polyethylene glycol (PEG), an osmotic laxative.
Option B: Option B is incorrect. A non-absorbable disaccharide fermented by colonic bacteria describes lactulose.
Option D: Option D is incorrect. Binding bile acids as an anion-exchange resin describes cholestyramine.
Option E: Option E is incorrect. GC-C receptor activation describes linaclotide and plecanatide.
5. Which agent approved for irritable bowel syndrome with constipation (IBS-C) works by inhibiting the sodium/hydrogen exchanger isoform 3 (NHE3) on intestinal epithelial cells?
A) Linaclotide
B) Plecanatide
C) Lubiprostone
D) Alosetron
E) Tenapanor
ANSWER: E
Rationale:
Option E is correct. Tenapanor inhibits the sodium/hydrogen exchanger isoform 3 (NHE3), the primary intestinal sodium-absorption transporter. Blocking it reduces sodium and water absorption, increasing luminal fluid and accelerating transit; it also reduces paracellular phosphate absorption and is separately approved for hyperphosphatemia in dialysis patients.
Option A: Option A is incorrect. Linaclotide is a guanylate cyclase-C (GC-C) agonist, not an NHE3 inhibitor.
Option B: Option B is incorrect. Plecanatide is also a GC-C agonist.
Option C: Option C is incorrect. Lubiprostone activates type-2 chloride (ClC-2) channels.
Option D: Option D is incorrect. Alosetron is a 5-HT3 receptor antagonist used in IBS-D.
6. Loperamide is a mu-opioid agonist, yet unlike morphine it produces no central opioid effects at standard doses. Which property most directly explains this difference?
A) Loperamide binds only kappa-opioid receptors
B) Loperamide is a high-affinity P-glycoprotein substrate that is pumped out at the blood-brain barrier, keeping central nervous system concentrations negligible
C) Loperamide is an antagonist rather than an agonist at mu-opioid receptors
D) Loperamide is not absorbed from the gut at all
E) Loperamide is metabolized to morphine only in the central nervous system
ANSWER: B
Rationale:
Option B is correct. Loperamide is an extremely high-affinity P-glycoprotein substrate at the blood-brain barrier; efflux keeps central nervous system concentrations negligible at standard doses. This peripheral selectivity gives antidiarrheal action without central opioid effects.
Option A: Option A is incorrect. Loperamide acts at mu-opioid receptors in the gut, not selectively at kappa receptors.
Option C: Option C is incorrect. Loperamide is an agonist at gut mu-opioid receptors, not an antagonist.
Option D: Option D is incorrect. Loperamide is absorbed but kept out of the brain by P-glycoprotein efflux; it is not simply unabsorbed.
Option E: Option E is incorrect. Loperamide is not converted to morphine in the central nervous system.
7. Bismuth subsalicylate carries cautions about use in children with viral illness and about interaction with anticoagulants. Which component of the drug is responsible for these specific concerns?
A) The salicylate moiety, which is systemically absorbed and represents a meaningful salicylate dose
B) The bismuth ion, which has direct antimicrobial activity
C) Bismuth sulfide, which forms in the gut and turns stools black
D) An anion-exchange resin component that binds other drugs
E) A quaternary ammonium group that limits central nervous system entry
ANSWER: A
Rationale:
Option A is correct. The salicylate moiety of bismuth subsalicylate is systemically absorbed and represents a clinically meaningful salicylate dose. As with aspirin, this underlies the Reye syndrome caution in children and teenagers with viral illness and the interaction with anticoagulants such as warfarin.
Option B: Option B is incorrect. The bismuth ion provides antimicrobial and toxin-binding effects but is not the basis for the Reye and anticoagulant cautions.
Option C: Option C is incorrect. Bismuth sulfide causes harmless black discoloration of stool and tongue, not the salicylate-related warnings.
Option D: Option D is incorrect. Bismuth subsalicylate is not an anion-exchange resin; that describes cholestyramine.
Option E: Option E is incorrect. A quaternary ammonium group limiting central nervous system entry describes methylnaltrexone, not bismuth subsalicylate.
8. According to current IDSA/SHEA guidelines, which agent is preferred for non-severe Clostridioides difficile infection (CDI) because it produces similar cure rates but lower recurrence than oral vancomycin?
A) Metronidazole
B) Loperamide
C) Fidaxomicin
D) Bezlotoxumab
E) Rifaximin
ANSWER: C
Rationale:
Option C is correct. Fidaxomicin, a minimally absorbed macrolide concentrated in the colon, is preferred for non-severe CDI because it produces cure rates similar to oral vancomycin with significantly lower recurrence for non-hypervirulent strains, attributed to its narrow spectrum sparing colonization-resistance flora.
Option A: Option A is incorrect. Metronidazole has been downgraded and is no longer first-line for any CDI severity.
Option B: Option B is incorrect. Loperamide is an antidiarrheal and is contraindicated in CDI because of toxic megacolon risk.
Option D: Option D is incorrect. Bezlotoxumab is a toxin B-neutralizing antibody for recurrence prevention, not a primary treatment agent.
Option E: Option E is incorrect. Rifaximin is used for traveler's diarrhea and hepatic encephalopathy, not as first-line CDI therapy.
9. The major virulence toxins of Clostridioides difficile (toxin A and toxin B) damage colonocytes through which biochemical action?
A) They form pores in the colonocyte membrane, causing osmotic lysis
B) They cleave ribosomal RNA, halting protein synthesis
C) They activate adenylate cyclase, raising cyclic adenosine monophosphate
D) They are glucosyltransferases that inactivate Rho family GTPases, disrupting the actin cytoskeleton and tight junctions
E) They inhibit bacterial RNA polymerase within the colonocyte
ANSWER: D
Rationale:
Option D is correct. Toxin A (TcdA) and toxin B (TcdB) are glucosyltransferases that inactivate Rho family GTPases within colonocytes. This disrupts the actin cytoskeleton and tight junctions, causing apoptosis and inflammatory cell recruitment; TcdB is the primary virulence determinant in human disease.
Option A: Option A is incorrect. The toxins act enzymatically on Rho GTPases rather than primarily forming membrane pores.
Option B: Option B is incorrect. Cleavage of ribosomal RNA is not the mechanism of these toxins.
Option C: Option C is incorrect. Adenylate cyclase activation describes cholera toxin, not C. difficile toxins.
Option E: Option E is incorrect. Inhibition of bacterial RNA polymerase describes the antibiotic fidaxomicin, not the toxins.
10. Eluxadoline is approved for diarrhea-predominant irritable bowel syndrome (IBS-D). Which receptor activity profile correctly describes it?
A) Pure mu-opioid receptor antagonist
B) Mu-opioid receptor agonist, kappa-opioid receptor agonist, and delta-opioid receptor antagonist
C) Selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist
D) Guanylate cyclase-C (GC-C) receptor agonist
E) Type-2 chloride (ClC-2) channel activator
ANSWER: B
Rationale:
Option B is correct. Eluxadoline is a mixed opioid receptor modulator: a mu-opioid receptor agonist, a kappa-opioid receptor agonist, and a delta-opioid receptor antagonist. The mu and kappa agonism reduce secretion and motility, while delta antagonism is intended to limit the constipating and nausea-inducing effects of full mu agonism.
Option A: Option A is incorrect. Eluxadoline is a mu-opioid agonist, not a pure antagonist.
Option C: Option C is incorrect. A selective 5-HT3 antagonist describes alosetron.
Option D: Option D is incorrect. GC-C receptor agonism describes linaclotide and plecanatide.
Option E: Option E is incorrect. ClC-2 channel activation describes lubiprostone.
11. Alosetron, used under a restricted program for severe diarrhea-predominant irritable bowel syndrome (IBS-D), acts at which receptor?
A) Mu-opioid receptor
B) Guanylate cyclase-C (GC-C) receptor
C) Type-2 chloride (ClC-2) channel
D) Sodium/hydrogen exchanger isoform 3 (NHE3)
E) 5-hydroxytryptamine type 3 (5-HT3) receptor
ANSWER: E
Rationale:
Option E is correct. Alosetron is a potent, selective antagonist of the 5-hydroxytryptamine type 3 (5-HT3) receptor on GI afferent neurons. Blocking it slows colonic transit, increases compliance, and reduces visceral afferent signaling, reducing stool frequency, urgency, and pain in IBS-D.
Option A: Option A is incorrect. Mu-opioid receptor activity describes loperamide and eluxadoline, not alosetron.
Option B: Option B is incorrect. GC-C receptor agonism describes linaclotide and plecanatide.
Option C: Option C is incorrect. ClC-2 channel activation describes lubiprostone.
Option D: Option D is incorrect. NHE3 inhibition describes tenapanor.
12. Linaclotide and plecanatide activate guanylate cyclase-C (GC-C) on the intestinal epithelial surface. Which intracellular second messenger rises as a result and drives both fluid secretion and pain reduction?
A) Cyclic guanosine monophosphate (cGMP)
B) Cyclic adenosine monophosphate (cAMP)
C) Inositol trisphosphate (IP3)
D) Diacylglycerol (DAG)
E) Calcium-calmodulin complex
ANSWER: A
Rationale:
Option A is correct. GC-C activation increases intracellular cyclic guanosine monophosphate (cGMP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR), driving chloride and bicarbonate secretion into the lumen, and also directly inhibits submucosal pain-sensing neurons, accounting for the analgesic benefit.
Option B: Option B is incorrect. Cyclic adenosine monophosphate (cAMP) is not the second messenger generated by GC-C activation.
Option C: Option C is incorrect. Inositol trisphosphate (IP3) is a phospholipase C pathway messenger, not the GC-C product.
Option D: Option D is incorrect. Diacylglycerol (DAG) is also a phospholipase C pathway messenger, not relevant here.
Option E: Option E is incorrect. The calcium-calmodulin complex is not the mediator of GC-C agonist action.
13. Bezlotoxumab reduces recurrence of Clostridioides difficile infection (CDI). What is its molecular target?
A) Bacterial RNA polymerase of C. difficile
B) The cell wall of vegetative C. difficile
C) C. difficile toxin B (TcdB)
D) The 5-hydroxytryptamine type 3 (5-HT3) receptor
E) Mu-opioid receptors in the colonic wall
ANSWER: C
Rationale:
Option C is correct. Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B (TcdB). Given as a single intravenous infusion during antibiotic therapy, it neutralizes TcdB to reduce recurrence rather than treating active infection.
Option A: Option A is incorrect. Inhibition of bacterial RNA polymerase describes the antibiotic fidaxomicin.
Option B: Option B is incorrect. Bezlotoxumab targets a secreted toxin, not the bacterial cell wall.
Option D: Option D is incorrect. The 5-HT3 receptor is the target of alosetron.
Option E: Option E is incorrect. Mu-opioid receptors are the targets of loperamide and the PAMORAs, not bezlotoxumab.
14. Cholestyramine is used to treat bile acid diarrhea. To which drug class does it belong?
A) Stimulant laxative
B) Peripherally acting mu-opioid receptor antagonist (PAMORA)
C) Guanylate cyclase-C (GC-C) agonist
D) Bile acid sequestrant (anion-exchange resin)
E) Osmotic laxative
ANSWER: D
Rationale:
Option D is correct. Cholestyramine is a bile acid sequestrant, an anion-exchange resin that binds bile acids in the intestinal lumen and prevents their colonic delivery, treating bile acid diarrhea. It is not absorbed but also binds many co-administered drugs, requiring dose separation.
Option A: Option A is incorrect. Stimulant laxatives are agents such as senna and bisacodyl.
Option B: Option B is incorrect. PAMORAs are agents such as methylnaltrexone and naloxegol.
Option C: Option C is incorrect. GC-C agonists are linaclotide and plecanatide.
Option E: Option E is incorrect. Osmotic laxatives are agents such as polyethylene glycol and lactulose.
15. Rifaximin is approved for traveler's diarrhea caused by noninvasive strains of enterotoxigenic Escherichia coli. Which property best characterizes rifaximin?
A) It is extensively absorbed and achieves high plasma concentrations
B) It is a minimally absorbed rifamycin derivative that achieves high intraluminal concentrations while producing negligible systemic antibiotic effect
C) It is a mu-opioid agonist that slows intestinal motility
D) It neutralizes enteric bacterial toxins by direct antibody binding
E) It activates chloride secretion to flush pathogens from the lumen
ANSWER: B
Rationale:
Option B is correct. Rifaximin is a minimally absorbed rifamycin derivative (less than 0.4 percent systemic bioavailability) that reaches high intraluminal antibiotic concentrations against enteric pathogens while producing negligible systemic antibiotic effect. It is therefore unsuitable when invasive pathogens (fever, dysentery) are likely.
Option A: Option A is incorrect. Rifaximin is minimally absorbed, not extensively absorbed with high plasma levels.
Option C: Option C is incorrect. A mu-opioid agonist slowing motility describes loperamide, not rifaximin.
Option D: Option D is incorrect. Toxin neutralization by antibody describes bezlotoxumab.
Option E: Option E is incorrect. Rifaximin is an antibiotic; it does not work by activating chloride secretion.
16. A hypervirulent lineage of Clostridioides difficile emerged in the 2000s and was associated with increased disease severity and recurrence. Which designation identifies this hypervirulent strain, which also produces binary toxin?
A) NAP1 (also known as ribotype 027)
B) Ribotype 014
C) Enterotoxigenic Escherichia coli (ETEC)
D) Vancomycin-resistant Enterococcus (VRE)
E) Ribotype 001 toxinotype 0
ANSWER: A
Rationale:
Option A is correct. The hypervirulent lineage is NAP1 (North American pulsotype 1), also known as ribotype 027. In addition to toxins A and B, it produces binary toxin (CDT), and its emergence was associated with increased severity and recurrence; the fidaxomicin recurrence advantage is not observed in this strain.
Option B: Option B is incorrect. Ribotype 014 is a common strain but is not the hypervirulent lineage in question.
Option C: Option C is incorrect. Enterotoxigenic Escherichia coli (ETEC) causes traveler's diarrhea, not CDI.
Option D: Option D is incorrect. Vancomycin-resistant Enterococcus (VRE) is a separate organism unrelated to C. difficile virulence typing.
Option E: Option E is incorrect. Ribotype 001 toxinotype 0 is not the hypervirulent NAP1/027 lineage described.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.